Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
12.90
-0.44 (-3.20%)
Feb 24, 2025, 3:02 PM EST - Market open
Aardvark Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -13.85 | -7.21 | -13.56 |
| Depreciation & Amortization | 0.16 | 0.1 | 0.11 |
| Loss (Gain) From Sale of Investments | 0.1 | 1.22 | 2.32 |
| Stock-Based Compensation | 0.34 | 0.31 | 0.41 |
| Provision & Write-off of Bad Debts | 0.29 | 0.76 | 0.49 |
| Other Operating Activities | - | -0.92 | 1 |
| Change in Accounts Payable | 0.54 | 0.78 | 0.03 |
| Change in Other Net Operating Assets | 0.92 | -0.86 | -1.34 |
| Operating Cash Flow | -11.52 | -5.82 | -10.54 |
| Other Investing Activities | - | - | -1 |
| Investing Cash Flow | -0.1 | - | -1 |
| Issuance of Common Stock | 0.17 | - | 0.23 |
| Financing Cash Flow | 83.01 | - | 0.23 |
| Net Cash Flow | 71.39 | -5.82 | -11.32 |
| Free Cash Flow | -11.62 | -5.82 | -10.54 |
| Free Cash Flow Per Share | -2.93 | -1.47 | -2.71 |
| Levered Free Cash Flow | - | -3.44 | - |
| Unlevered Free Cash Flow | - | -3.44 | - |
| Change in Net Working Capital | - | -0.78 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.